Information Meeting. March 9, 2018 Eisai Co., Ltd.
|
|
- Clemence Dixon
- 5 years ago
- Views:
Transcription
1 Information Meeting March 9, 2018 Eisai Co., Ltd.
2 Safe Harbor Statement Forecast or target figures in this material are not official earnings guidance but represent midterm strategies, goals, and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (Consolidated Financial Statement) in accordance with the rules set by Tokyo Stock Exchange. Materials and information provided during this presentation may contain so-called forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail. The Company discloses its consolidated financial statements according to the International Financial Reporting Standards(IFRS) 1
3 Imperatives for Plan EWAY 2025 Strategic Partners and New Business Model 2
4 Strategic Partnership With Merck & Co., Inc., Kenilworth, N.J., U.S.A. A new alliance in Cancer Evolution Era has just started 3
5 Intent for Collaboration Aim to realize value creation for patients with cancer in Cancer Evolution Era through innovative business model 4
6 Summary of collaboration Aim to promptly obtain new indications through co-development of LENVIMA Initiation of new co-development of the combination of LENVIMA and KEYTRUDA simultaneously for 11 regimens in six types of cancer and multiple cancer types in a basket trial to maximize patient contribution through the synergistic effects of LENVIMA and KEYTRUDA Collaboration aiming at expansion of access for LENVIMA Eisai, who has obtained a wealth of medical data on LENVIMA, and Merck & Co., Inc., Kenilworth, N.J., U.S.A., with its strong commercial footprint and medical expertise that spans the globe, are expediting the maximization of patient access to LENVIMA through joint commercialization and clinical activities Eisai to manufacture and book sales of LENVIMA. Companies to share development and marketing costs equally, as well as profits from LENVIMA. 5
7 Changes in tumor diameter (%) Changes in tumor diameter (%) Combination Therapy Rationale Observations from Phase Ib/II study targeting seven types of cancer *1 Metastatic renal cell carcinoma (30 patients) ORR *2 : 63% Tumor response was observed regardless of PD-L1 expression *3 Endometrial carcinoma (23 patients) ORR *4 : 52.2% Tumor response was observed regardless of MSI *5 status *6 (Anti-PD-1 antibodies are associated with high response rates in patients with MSI-H or dmmr *7 tumors) PD-L1 positive PD-L1 negative Unknown Low or negative MSI status Unknown MSI status Equivocal MSI status High or positive MSI status 6 Remarkable effect observed in combination therapy, exceeding efficacy of single agent administration All projects are investigational *1: Renal cell carcinoma, endometrial carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, non-small cell carcinoma, melanoma, hepatocellular carcinoma *2: Ratio of total of patients whose tumor had disappeared (complete response) and patients with tumor in which more than 30% shrinkage to the total size was observed (partial response). *3: Presented at European Society for Medical Oncology (ESMO) 2017 Congress. Lee CH, et al. A Phase 1b/2 Trial of Lenvatinib + Pembrolizumab in Patients With Renal Cell Carcinoma. Abstract No. 847O *4: Based on an independent radiologic review (IRR) *5: Microsatellite instability *6: Presented at 2017 American Society of Clinical Oncology Annual Meeting. Makker V, et al. A Phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with endometrial carcinoma *7: Deficient mismatch repair
8 Approved Indications and Projects Under Review/Investigational Ongoing Projects Thyroid cancer 1 st line monotherapy Renal cell carcinoma 2 nd line combination therapy with everolimus Hepatocellular carcinoma 1 st line monotherapy* Renal cell carcinoma 1 st line* Combination therapy with everolimus or with KEYTRUDA Approved in more than 50 countries Approved in more than 40 countries Simultaneous submissions achieved in 4 global regions Phase III study ongoing Aim to expand market coverage Aim to accelerate development Aim to expand market coverage for approved indications through co-commercialization, including increase in approved countries Aim to maximize patient contribution by accelerating investigational ongoing projects through co-development 7 * Investigational
9 8 Aim to Promptly Obtain New Indications Initiate multiple clinical studies aiming at indication/regimen expansion by advancing currently ongoing Phase Ib/II study Ongoing Phase Ib/II study Study 111 Renal cell carcinoma (RCC), endometrial carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, non-small cell carcinoma, melanoma Study 116 Hepatocellular carcinoma Breakthrough Therapy Designation granted by U.S. FDA for the indication of RCC Endometrial carcinoma Head and neck cancer Bladder cancer Non-small cell lung cancer Melanoma Hepatocellular carcinoma Develop multiple regimens in each type of cancer Basket trial targeting multiple cancer types Aim to realize the synergistic effect by simultaneously advancing clinical studies; renal cell carcinoma aiming at potential early approval based on granted Breakthrough Therapy designation, clinical studies for 11 regimens in six types of cancer, and a basket trial targeting multiple cancer types All projects are investigational.
10 Expansion of Access Expand access to LENVIMA through global networks of both companies Eisai global: Medical Affairs: approx.140 Oncology dedicated sales reps: approx. 540 EMEA Medical Affairs :approx. 40 Oncology dedicated sales reps: approx. 150 Japan Medical Affairs :approx. 20 Oncology dedicated sales reps*: approx. 140 US Medical Affairs: approx. 50 Oncology dedicated sales reps: approx. 120 China Medical Affairs: approx. 10 Oncology dedicated sales reps: approx. 30 Asia Medical Affairs: approx. 20 Oncology dedicated sales reps: approx. 100 Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strong commercial footprint and medical expertise that spans the globe Aim to expand access to LENVIMA through optimal resource allocation based on the agreement 9 * In addition to oncology dedicated sales reps, approx. 980 sales reps also co-operate oncology marketing
11 Forecast of Revenue and Profit for LENVIMA Revenue and profit will significantly exceed the Eisai sole development/promotion case with potential expansion of 11 regimens in six types of cancer and potential synergy effects from co-commercialization utilizing networks of both companies Accelerate development aiming for indication expansion across multiple cancer types with efficient investment in R&D Due to improvement in SG&A cost efficiency, profit of LENVIMA will significantly increase ( 億円 ) (billions of yen) 共同開発による Expansion of indications 新たな適応症の急伸拡大 Increase from the collaboration 5, 共同販促によるアクセスの拡大 Expansion of access エーザイ単独 Eisai alone (billions ( 億円 of yen) ) エーザイ単独 Eisai alone 2, FY2017 forecast FY2021 target Illustration of revenue growth simulation of LENVIMA * * Illustration based on given success case 0 FY2017 年度 forecast 見通し FY2021 年度 target 目標 2025 年度目標 Illustration of profit growth simulation of LENVIMA *
12 Launched product Halaven Microtubule dynamics inhibitor MORAb-202 Antibody-drug conjugate (ADC) E7130 *1 Halichondrin analogue Oncology Pipeline excluding Lenvima Biologics Middle molecule compound Small molecule compounds Submitted breast cancer indication in China in FY2017 Phase I/II study ongoing for triple negative breast cancer in combination with KEYTRUDA Aim for Eisai s first ADC comprising farletuzumab (MORAb-003), an investigational anti-folate receptor alpha (FRA) antibody with a payload eribulin (active ingredient of the launched, inhouse developed anti-cancer agent Halaven) Phase I study ongoing for FRA expressing solid tumors Topline results for Phase II study anticipated in FY2020 Aiming at treatment for rare cancer as a middle molecule microenvironment ameliorative agent by inhibiting microtubule dynamics: Utilizing Eisai s world-class modern synthetic organic chemistry, with the aim to create a new innovative compound like Halaven Phase I study ongoing for rare cancer E7386 *2 CBP/Beta-catenin inhibitor H3B-8800 SF3B1 modulator H3B-6527 FGFR4 inhibitor Aim to develop as a first-in-class molecular targeted agent of protein-protein interaction inhibitor that inhibits interaction of CBP/ beta-catenin located downstream of Wnt signaling pathways Phase I study ongoing for solid tumors with activated Wnt signaling pathways Frequency of spliceosome gene mutation is approx. 50% to 60% *3 in chronic myelomonocytic leukemia (CMML): Aiming for potential new treatment option as a splicing modulator in patients with hematological malignancies Phase I study ongoing for hematological malignancies with spliceosome gene mutation Topline results for Phase II anticipated in FY2019 Overexpression of driver gene FGF19 (FGFR4 ligand) in approx. 35% *3 of hepatocellular carcinoma (HCC) patients: Aim for new treatment option in patients with HCC Phase I study ongoing for hepatocellular carcinoma (HCC) with overexpression of FGF19 11 H3B-6545 ESR1 inhibitor E7090 FGFR1,2,3 inhibitor Potential to treat patients with estrogen receptor (ER) positive breast cancer, as a first-in-class estrogen receptor 1 (ESR1) covalent antagonist Phase I study ongoing for ER positive breast cancer Aim for targeted therapy based on cancer genome information Phase I study ongoing for gastric cancer with FGFR2 gene amplification and intrahepatic cholangiocarcinoma with FGFR2 gene fusion All projects are investigational. *1: Co-created compound with Harvard University *2: Co-development with PRISM Pharma *3: Internal estimates
13 Strategic Partnership With Biogen: The strongest allies for creating Alzheimer s disease (AD) treatments 12
14 Aducanumab * Phase III Program is Steadily Ongoing Blinded sample size re-estimation for ENGAGE and EMERGE was preplanned per protocol in case of variability from original assumptions As per the reevaluation of variability on the primary endpoint, sample size was adjusted as planned in order to maintain 90% study power (additional 255 patients per study: total of 1605 patients per study) The program is ongoing as planned with sample size of 1605 patients per study, which is the similar setting to other Phase III programs studying disease modifiers for Alzheimer s Disease Patient enrollment is steadily ongoing, with completion of patient enrollment anticipated in mid-2018, regardless of increase in the sample size Neither the probability of success of Phase III studies nor whole plan of the programs are impacted 13 * Investigational. Co-development with Biogen.
15 Effect of BAN2401 BAN2401 * Characteristics of A-beta Clearance BAN2401 has A-beta clearance effect by binding to A-beta protofibrils that are believed to be highly toxic A-beta protofibrils Soluble A-beta aggregates High toxicity Induce neurodegenerative process and cause neuronal cell death A-beta fibrils Insoluble A-beta aggregates Disease progression of dementia Risk of ARIA *2 Removal of brain amyloid is associated with increased the risk of ARIA Accumulation of A-beta potentially has a negative effect on dementia disease progression Binds to A-beta protofibrils Clearance of highly toxic A-beta protofibrils (soluble aggregates) Potential risk of ARIA is lower with weaker effect on for A-beta fibrils (insoluble A-beta aggregates) 14 *1: Investigational. Co-development with Biogen. Licensed in from BioArctic. *2: Amyloid related imaging abnormalities with cerebral edema (ARIA-E) or with cerebral microhaemorrhages (ARIA-H)
16 Investigational Elenbecestat *1 Pursuit of Potential as BACE1 Inhibitor in AD Treatment Relative selectivity to BACE1 is sought for BACE inhibitors for AD treatments 1. Inhibition of BACE1 is important since BACE1 is potentially related to A-beta production in brain 2. Selectivity of substrates of BACE1/2 is important since neuronal cell maintenance, synaptic formation and brain immunity may be impacted by them *2 BACE1 *4 BACE2 *4 BACE2/BACE1 *5 50% inhibitory concentration (nm)* 3 of elenbecestat Elenbecestat demonstrates relative selectivity to BACE1 Phase III Studies ongoing MISSION AD1 MISSION AD2 *6 Clinical studies underway at 421 sites *7, and plan for a total of 480 sites in FY2017 Plan to initiate clinical studies in China in March 2018 Enrollment of patients in early disease stage ongoing as planned (over 75%: prodromal, less than 25%: mild AD) Topline results for primary endpoint anticipated in FY *1: Generic name for E2609. The generic name is not yet fixed at this time. Co-development with Biogen. *2: Voytyuk et al, Life Science Alliance 2018, 1 *3: Internal data *4: Smaller number indicates stronger activity *5: Larger number indicates higher selectivity to BACE1 *6: Names of E2609 Phase III studies (AD1 is Study 301, AD2 is Study 302) *7: As of February 28, 2018
17 Parallel Progression of AD Pathology and Transformation of Symptoms of Various Aggressive Factors Total care by the combination of different mechanisms of action depending on the disease stages and symptoms of patients Disease stages Preclinical AD Prodromal AD AD Pathology of aggressive factors A-beta pathology Tau pathology Early anti-a-beta treatment BACE inhibitor + anti-a-beta antibody Treatment based on aggressive factors Prevention of onset Inhibition of progress Progression of disease Anti-A-beta maintenance treatment BACE inhibitor ±Anti-A-beta antibody (intermittent treatment etc.) Anti-A-beta treatment and anti-tau treatment BACE inhibitor + anti-a-beta antibody + anti-tau antibody Inhibition of progress Anti-A-beta and anti-tau maintenance treatment BACE inhibitor ±Anti-A-beta antibody (intermittent treatment etc) ± anti-tau antibody (intermittent treatment etc) 16 Treatment based on transformation of symptoms over time Sleep disorder Behavior disorder (epilepsy) * All projects are investigational except for Aricept *1: Co-development with Purdue Pharma Lemborexant *1 Cognitive disorder E2082 and E2730 Aricept and E2027
18 Lemborexant *1 Dual orexin receptor antagonist Phase III study in patients with difficulty staying asleep through the night *2 (Controlled study in patients age 55 years and older with active comparator zolpidem ER and placebo) Achieved primary endpoint Achieved primary and key secondary objectives against placebo and zolpidem ER on sleep onset and sleep maintenance variables, including the time spent awake in the second half of the night Phase I study (Study 106): Evaluate next day effects by measuring impairment of driving performance (Driving study) No carry-over effect in the following morning observed in the assessment of primary endpoint Phase I study (Study 108) *3 : Post-dose safety evaluation in the middle of night awakening in healthy volunteers 55 and older Met its primary endpoint demonstrating that postural stability was clinically meaningfully worse for zolpidem ER as compared with both treatment arms of lemborexant A novel sleep disorder treatment suitable for elderly patients; efficacy in sleep onset and sleep maintenance without clinically meaningful next morning effects 17 *1: Investigational. Co-development with Purdue Pharma. *2: Most common AEs in the lemborexant arms were headache and somnolence *3: The only AE observed in the lemborexant arms was headache
19 Projects targeting progress of aggressive factors accumulation in dementia-related field Lemborexant *1 Dual orexin receptor antagonist Neurology Pipeline Projects targeting transformation of symptoms over time in dementia-related field Non-dementia projects Sleep disorders Plan to submit in FY2018 Study 304: Controlled study in 1,006 patients age 55 years or older with active comparator zolpidem ER and placebo Obtained favorable topline results in March 2018 Study 303: Twelve-month, efficacy and safety study (six-month placebo-controlled study) Topline results anticipated in FY2018 ISWRD *2 due to AD/dementia Phase II study ongoing Topline results anticipated in early FY2018 Aducanumab *3 Anti-A-beta antibody Elenbecestat *3,4 BACE Inhibitor Early AD Phase III studies ongoing Last patient in (LPI) anticipated in mid 2018 Early AD Phase III studies ongoing Topline results anticipated in FY BAN2401 *3,5 Anti-A-beta protofibrils antibody E6011 Anti-fractalkine antibody E2027 PDE9 inhibitor E2730 Synaptic functional modulator E2082 Next generation AMPA receptor antagonist E2814 In-house discovered anti-tau antibody Early AD Phase II study ongoing Comprehensive evaluation from the final analysis at 18 months anticipated in Q Rheumatoid arthritis Phase II study ongoing Study 201 (in patients who have had an inadequate response to methotrexate) Topline results anticipated in Q1 FY2018 Study 202 (in patients who have had an inadequate response to biologics) Topline results anticipated in Q2 FY2018 Dementia with Lewy bodies Phase II study under preparation Epilepsy and other neurological disorders Phase I study ongoing Epilepsy and other neurological disorders Phase I study ongoing AD/dementia Initiation of Phase I study anticipated in FY2018 All projects are investigational. *1: Co-development with Purdue Pharma *2: Irregular sleep-wake rhythm disorder *3: Co-development with Biogen *4: Generic name for E2609.The generic name is not yet fixed at this time. *5: Licensed in from BioArctic
20 New Business Model Eisai AD Ecosystem by Platform Model 19
21 Architecture of the Eisai AD Ecosystem Comprised of Members, Partners and Platform Members Partners (Contents layers) Platform 20
22 Eisai s Dementia Platform Disease awareness Provide information on dementia through e-65.net* 1 Enhance awareness through TV ads Operate forums for citizens in collaboration with local government Collaboration with dementia support organizations Educational materials on dementia for elementary and secondary school students Treatment/Care options Provide information on social resources for dementia through e-65.net Aricept s various formulations to fulfill patients needs Indication of Aricept for dementia with Lewy bodies Medicine adherence support device e-okusuri-san Early diagnosis Eisai original diagnostic scale/treatment effect measure such as ADCOMS* 2 VSRAD* 3, diagnosis support software for early AD Collaboration with key opinion leaders in the field of dementia through academic meetings, education for physicians how to diagnose dementia and other activities Dementia-related clinical data Accumulate the data through development of disease modifiers Clinical data and post marketing clinical data of Aricept Real world data through Living Labs. Community networking Long-term activities to support patients with dementia and community networking with 527 communities in Japan Collaboration with local government (Agreement with 130 communities as of end of February 2018) Wellness Open. Living Labs. (2 sites as of end of February 2018) Interprofessional collaboration service Hikari One Team SP Tracking tool to support people with dementia and Seniors going out Me- MAMORIO Provide information and consultation Provide information on social resource map with medical institutions and regional support facilities on dementia through e- 65.net Respond to customers inquiries on dementia through hhc Hotline (since Aricept launched in 1999, approx. 140,000 inquiries have been received as of end of February 2018) Dementia diagnosis lump-sum insurance Dementia Support 21 Eisai s defining quality *1: e-65.net: Website for disease awareness and provision of information for patients with dementia and their families run by Eisai (only available in Japanese) *2: Alzheimer s Disease Composite Score (Pursue potential for diagnosis/scale to measure disease progression in the future) *3: Voxel-Based Specific Regional Analysis System for Alzheimer's Disease
23 Characteristics of Eisai s AD Ecosystem Eisai s dementia platform with robust connection with patients and their families Utilize local residents to gain knowledge of how to fulfill their true needs Socialization Recognize issues through socialization Internalization Examine the impact of solution Externalization Externalize ideas to solve problem based on socialization Combination Compile ideas as a solution to solve issues Platform centering on Eisai s superiority of clinical data More than 30 years of accumulated know-how and deep insight through Medicine Creation activities in dementia field Accumulated data in various disease stages (early to severe) through 40 double blind studies on dementia Human Capital with abundant experience in clinical studies Network with KOLs and medical facilities for clinical studies Knowledge of community networking with local communities gained through partnership agreements for dementia Sharing issues and needs for initiatives toward dementia Partnership agreement for dementia Develop plans to solve issues through council Validation through local communities Aim to enhance initiatives for community networking Implement activities for community networking at local governments with partnership agreement (130 communities *1 and approx. 25 million people *2 ) and Living Labs. (2 sites *1 and approx. 1.5 million people *2 ) 22 *1: As of end of February 2018 *2: Figures are approximate based on disclosed information on the websites of local governments
24 Category Design for AD Ecosystem Category: implement new technologies and ideas based on feedback from patients and their families Case of category design: design new categories through segmentation of patients hope not to get dementia Hope not to get dementia Hope to stay healthy Want to know how to prevent Hope for preventive medicine Anxiety regarding burden on caregivers or families Hope to live longer with family Hope for early diagnosis and early treatment Want to avoid causing any financial troubles Preventive medicine or disease modifiers for dementia Diet, lifestyle and exercise verified by science System for patients suspected to have dementia to enroll in appropriate clinical studies Websites to answer concerns about care System to search nursing care facilities which patients could spend time with their families Simple blood test to detect dementia Medical insurance to cover cost of treatment and care 23
25 Perspective for Plan EWAY 2025 Transformation to Platform Business Model from Value Chain Business Model 24 Enabling further proactive investment in R&D aiming to realize treatment for cure in Cancer Evolution and Preemptive Medicine in treatment for Alzheimer s disease Potential achievement of 100B yen level operating profit on average and 10% level ROE The achievability of EWAY (mid-term business plan) target is enhanced The achievability of FY2025 ROE target of 15% level is enhanced through continuous growth in revenue and operating profit beyond FY2021
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationQ2 FY2017. Financial Results Presentation
Q2 FY2017 (Fiscal Year Ending March 31, 2018) Financial Results Presentation Eisai Co., Ltd. November 1, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain
More informationQ1 FY2017. Financial Results Presentation
Q1 FY2017 (Fiscal Year Ending March 31, 2018) Financial Results Presentation Eisai Co., Ltd. August 2, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information+81-(0)
FOR IMMEDIATE RELEASE Contacts: Eisai Co., Ltd. Purdue Pharma L.P. Public Relations Department Danielle Lewis +81-(0)3-3817-5120 +1-203-588-7653 Positive New Data on Investigational Lemborexant Presented
More informationFY2016. Financial Results Presentation
FY2016 (Fiscal Year Ended March 31, 2017) Financial Results Presentation Eisai Co., Ltd. May 10, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain so-called
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More information11. Major R&D Pipeline In-House R&D Pipeline List
11. Major R&D Pipeline In-House R&D Pipeline List Product Name / Development Code Additional Indication, etc.** Development Stage*** Therapeutic Area**** New Approval Fycompa (Monotherapy for partial-onset
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More information- Amendment accelerates anticipated PROSPER top-line results by two years -
Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationDainippon Sumitomo Pharma
Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationFY 2018 (Ending March 31, 2019) Second Quarter Financial Results. Reference Data. November 1, Eisai Co., Ltd.
Securities Code: 4523 FY (Ending March 31, 2019) Second Quarter Financial Results Reference Data November 1, Eisai Co., Ltd. For Inquiries: Public Relations: TEL +81-(0)3-3817-5120 Investor Relations:
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationInformation Meeting. March 7, 2014 Eisai Co., Ltd.
Information Meeting March 7, 2014 Eisai Co., Ltd. Safe Harbor Statement Forecast or target figures in this material are not official earnings guidance but present the midterm strategies, goals, and visions.
More informationFiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd.
Fiscal Year 2003 Consolidated 1 st Quarter Business Performance Eisai Co., Ltd. 1 Consolidated 1 st Quarter Performance Net Sales A Start According to Plan 2002 st Quarter 1 st 115.2 2003 st Quarter 1
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More information3Q FY2011 (Fiscal Year Ending March 31, 2012) Financial Results Presentation Eisai Co., Ltd.
3Q FY2011 (Fiscal Year Ending March 31, 2012) Financial Results Presentation Eisai Co., Ltd. February 2, 2012 Safe Harbor Statement Materials and information provided during this presentation may contain
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationStrategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd.
Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd. - Aiming to Create New Business Models and Expand Contribution to Patients - March 29, 2018
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationPSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More information